PEDF inhibits growth of retinoblastoma by anti-angiogenic activity

Cancer Science

Volumn 100, Issue 12, 2009, Pages 2419-2425

  Yang, Huasheng ^a   Cheng, Rui ^b   Liu, Guoying ^a   Zhong, Qinghua ^b   Li, Chaoyang ^a   Cai, Weibin ^b,c   Yang, Zhonghan ^b   Ma, Jianxing ^d   Yang, Xia ^b   Gao, Guoquan ^b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; EYE PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; NERVE GROWTH FACTORS; RECOMBINANT PROTEINS; RETINAL NEOPLASMS; RETINOBLASTOMA; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70649083017     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01332.x     Document Type: Article

References (38)

1. Shields OL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control 2004, 11:317-27.
2. Schultz KR, Ranade S, Neglia JP. An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj Maharashtra, India. Cancer 1993, 72:282-6.
3. Chantada G, Fandino A, Manzitti J. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child 1999, 80:171-4.
4. Friedman DL, Himelstein B, Shields CL. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000, 18:12-7.
5. Cao W, Tombran-Tink J, Elias R. In vivo protection of photoreceptors from light damage by pigmentepithelium-derived factor. Invest Ophthalmol Vis Sci 2001, 42:1646-52.
6. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991, 53:411-4.
7. Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C. Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat Neurosci 2006, 9:331-9.
8. Zhang SX, Wang JJ, Gao G. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006, 20:323-5.
9. Stellmach V, Crawford SE, Zhou W. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001, 98:2593-7.
10. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006, 12:497-502.
11. Volpert OV, Zaichuk T, Zhou W. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002, 8:349-57.
12. Zhang SX, Wang JJ, Gao G. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006, 37:1-12.
13. Ho TC, Chen SL, Yang YC. Cytosolic phospholipase A2-α is an early apoptotic activator in PEDF-induced endothelial cell apoptosis. Am J Physiol Cell Physiol 2009, 296:C273-84.
14. Ho TC, Chen SL, Yang YC. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 2007, 76:213-23.
15. Steele FR, Chader GJ, Johnson LV. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 1993, 90:1526-30.
16. Garcia M, Fernandez-Garcia NI, Rivas V. Inhibition of xenografted human growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004, 64:5632-42.
17. Streck CJ, Zhang Y, Zhou J. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 2005, 40:236-43.
18. Zhu B, Lu L, Cai W. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007, 6:3297-306.
19. Wang QS, Yang X, Yang ZH. Novel method for expression and purification of human pigment epithelium-derived factor with biological activities in Escherichia coli. Prep Biochem Biotechnol 2006, 36:127-38.
20. Weidner N, Semple JP, Welch WR. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
21. Zhang T, Guang YL. Production of active pigment epithelium-derived factor in E. coli. Biotechnol Lett 2005, 27:403-7.
22. Dawson DW, Volpert OV, Gillis P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-8.
23. Duh EJ, Yang HS, Suzuma I. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002, 43:821-9.
24. Wang L, Schmitz V, Perez-Mediavilla A. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003, 8:72-9.
25. Stratikos E, Alberdi E, Gettins PG. Recombinant human pigment epithelium-derived factor (PEDF): characterization of PEDF overexpressed and secreted by eukaryotic cells. Protein Sci 1996, 5:2575-82.
26. Sánchez-Sánchez F, Aroca-Aguilar JD, Segura I. Expression and purification of functional recombinant human pigment epithelium-derived factor (PEDF) secreted by the yeast Pichia pastoris. J Biotechnol 2008, 134:193-201.
27. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-8.
28. Apte RS, Harbour JW. Inhibiting angiogenesis in retinoblastoma. Ophthalmic Res 2007, 39:188-90.
29. Poulaki V, Mitsiades CS, McMullan C. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci 2005, 46:358-66.
30. Gao G, Li Y, Gee S. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002, 277:9492-7.
31. Gao G, Li Y, Zhang D. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001, 489:270-6.
32. Leung DW, Cachianes G, Kuang WJ. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-9.
33. Choi YK, Kim JH, Kim WJ. AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. J Neurosci 2007, 27:4472-81.
34. Jia RB, Zhang P, Zhou YX. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 2007, 39:108-15.
35. Mizokami K, Kakeji Y, Oda S. Clinicopathologic significance of hypoxia-inducible factor1 alpha overexpression in gastric carcinomas. J Surg Oncol 2006, 94:149-54.
36. Yeo EJ, Chun YS, Cho YS. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003, 95:516-25.
37. Stoeltzing O, McCarty MF, Wey JS. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004, 96:946-56.
38. Lu L, Yang Z, Zhu B. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 2007, 257:97-106.